Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02306356
Other study ID # 2014/1225-31/4
Secondary ID
Status Completed
Phase N/A
First received September 27, 2014
Last updated January 18, 2016
Start date September 2014
Est. completion date October 2015

Study information

Verified date January 2016
Source Karolinska Institutet
Contact n/a
Is FDA regulated No
Health authority Sweden: Regional Ethical Review Board
Study type Interventional

Clinical Trial Summary

An open trial will be conducted at the Child and Mental Health Service (CAMHS) unit in the rural county Jämtland in Sweden to test the feasibility and efficacy of Internet-delivered Cognitive Behavior Therapy (ICBT) for children with anxiety disorders in a clinical setting. 20 children with a principal diagnosis of Generalized Anxiety Disorder (GAD), separation anxiety, specific phobia and their parents will be recruited from the CAMHS-center in Östersund. They will receive 12 weeks of therapist-supported ICBT and will be assessed by clinician ratings and child- and parent-reports at baseline, post-treatment and 3 month follow-up. The primary outcome measures the Clinical Global Impressions - Severity scale (CGI-S). Secondary outcome measures include clinician rated global functioning, and child and parent-rated anxiety and functioning.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender Both
Age group 8 Years to 12 Years
Eligibility Inclusion Criteria:

- 8-12 years of age

- Fulfilling diagnostic criteria for Generalized Anxiety Disorder (GAD), Separation anxiety, Specific phobia

- Ability to read and write Swedish

- Daily access to the internet

- A parent that is able to co-participate in the treatment

- Participants on psychotropic medication must have been on a stable dose for the last 3 months prior to baseline assessment

Exclusion Criteria:

- Diagnosed autism spectrum disorder or Attention-deficit/hyperactivity disorder (ADHD), or principal primary disorder other than GAD, Separation anxiety, Specific phobia

- Acute/severe psychiatric problems such as suicidal risk or severe depression

- Ongoing psychological treatment for anxiety disorders

- Ongoing child custody dispute or abuse in the family

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Behavioral:
Internet-delivered Cognitive Behavior Therapy


Locations

Country Name City State
Sweden Child and Adolescent Mental Health Services Östersund Östersund Jämtland

Sponsors (2)

Lead Sponsor Collaborator
Karolinska Institutet BUP Östersund

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Clinical Global Impressions - severity (CGI-S) Change in CGI-s from baseline to post-treatment and follow-up baseline, post-treatment (12 weeks), follow-up (3 months) No
Secondary Children´s Global Assessment Scale (CGAS Baseline, post-treatment (12 weeks), follow-up (3 months) No
Secondary Spence Child Anxiety Scale C/P (SCAS-C/P) Baseline, post-treatment (12 weeks), follow-up (3 months) No
Secondary Penn State Worry Questionnaire (PSWQ) Baseline, post-treatment (12 weeks), follow-up (3 months) No
Secondary Separation Anxiety Index (SAI) Baseline, post-treatment (12 weeks), follow-up (3 months) No
Secondary Fear Survey Schedule for Children - Revised (FSSC-R) Baseline, post-treatment (12 weeks), follow-up (3 months) No
Secondary Child Sheehan Disability Scale (CSDS) Baseline, post-treatment (12 weeks), follow-up (3 months) No
Secondary Child Depression Inventory (CDI) Baseline, post-treatment (12 weeks), follow-up (3 months) No
Secondary Hospital Anxiety Depression Scale (HAD) Baseline, post-treatment (12 weeks), follow-up (3 months) No
Secondary Client Satisfaction Scale (CSS) post-treatment (12 weeks) No
Secondary Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P) Baseline, post-treatment (12 weeks), follow-up (3 months) No
See also
  Status Clinical Trial Phase
Terminated NCT03420456 - Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Withdrawn NCT02382224 - Worry Exposure for Generalized Anxiety Disorder N/A
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Completed NCT01958788 - Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder N/A
Completed NCT01681329 - Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder N/A
Completed NCT01201967 - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Phase 4
Completed NCT01342120 - PHARMO Institute Seroquel Safety Study N/A
Completed NCT01337713 - Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD) N/A
Completed NCT01203293 - Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector Phase 1
Completed NCT00961298 - An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Phase 4
Completed NCT01971203 - Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat N/A
Terminated NCT01244711 - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines Phase 4
Completed NCT00744627 - Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults. Phase 3
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Completed NCT00537615 - An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers Phase 1
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00515242 - Therapeutic Massage for Generalized Anxiety Disorder Phase 1/Phase 2
Completed NCT00620776 - Combined Treatment for Generalized Anxiety Disorder (GAD) Phase 2
Completed NCT00368745 - Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use. Phase 3